Heart Failure Therapeutics in Asia-Pacific Markets to 2024-Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy
The New Report “Heart Failure Therapeutics Market” published by Premium Market Insights, covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Heart failure (HF) is a life-threatening syndrome with substantial morbidity and mortality. There are more than 26 million people with HF globally and this is increasing because of the rapidly aging population. HF is a major global healthcare problem as the number of HF patients is increasing. It has the greatest negative impact on quality of life compared with other major chronic disease, such as diabetes, arthritis, and hypertension.
HF has been gradually rising in the Asia-Pacific region, with the growing elderly population and increasingly Westernized lifestyles. Increasing risk factors will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth. Despite therapeutic advances, the morbidity and mortality associated with HF continues to be considerable, particularly in elderly patients.
In fact, most hospitalizations and deaths attributable to HF occur in people aged above 65. About half of all patients diagnosed with HF die within five years and the five-year survival rate is lower than that associated with other malignancies. The poor long-term prognosis associated with HF has created a pressing need for improved therapeutic options. The marketed products landscape comprises a wide range of treatment options, including ARN-targeted therapy, ACE inhibitors, ATR blockers, If channel inhibitor, beta blockers, MRAs and diuretics.
Get sample copy of “Heart Failure Therapeutics Market” at: https://www.premiummarketinsights.com/sample/GBI00004576
-The HF Asia-Pacific market will be valued at $1,435.9m in 2024, growing from $733.7m in 2017 at a CAGR of 10.1%.
-How would the approval of Entresto to treat HF-PEF patients affect the competitive landscape, with no therapy currently available to address this patient subset?
-The HF market is crowded with cheap, generic, ?me-too? drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the HF market?
-The pipeline for HF therapies is quite diverse with a range of molecule types and molecular targets.
-Which molecular targets appear most frequently in the pipeline?
-How have the late-stage therapies performed in clinical trials?
-The level of unmet needs in the HF market is significantly high. Will the pipeline drugs fulfill these unmet needs of the market?
-The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.
-How will the annual cost of therapy and market size vary between the five assessed Asia-Pacific markets?
-How could changes in risk factors such as population age, CVD and lifestyle influence the market?
-Various drivers and barriers will influence the market over the forecast period.
-Licensing deals are the most common form of strategic alliance in HF, with total deal values ranging from under $0.072m to over $1000m.
-How do deal frequency and value compare between target families and molecule types?
-What were the terms and conditions of key licensing deals?
Have any query? Enquire about report at: https://www.premiummarketinsights.com/discount/GBI00004576
Fundamentals of Table of Content:
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Heart Failure Therapeutics Market Size
2.2 Heart Failure Therapeutics Growth Trends by Regions
2.3 Industry Trends
3 Market Share by Key Players
3.1 Heart Failure Therapeutics Market Size by Manufacturers
3.2 Heart Failure Therapeutics Key Players Head office and Area Served
3.3 Key Players Heart Failure Therapeutics Product/Solution/Service
3.4 Date of Enter into Heart Failure Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Heart Failure Therapeutics Sales by Product
4.2 Global Heart Failure Therapeutics Revenue by Product
4.3 Heart Failure Therapeutics Price by Product
5 Breakdown Data by End User
5.2 Global Heart Failure Therapeutics Breakdown Data by End User
Get Complete Report at: https://www.premiummarketinsights.com/buy/GBI00004576
Email: [email protected]
Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.